Tumor Microenvironment-Responsive Nanomedicine: Monitoring and Modulating the Tumor Microenvironment for Precision Cancer Therapy
Open accessThe DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Abstract
The tumor microenvironment (TME) is a dynamic and heterogeneous ecosystem whose abnormal vasculature, dense extracellular matrix, metabolic reprogramming and immunosuppression collectively hinder drug penetration, drive therapeutic resistance and limit responses to immunotherapy. TME-responsive nanomedicine provides an emerging toolbox to both monitor and actively remodel the microenvironment for precision cancer therapy. In this narrative review, we first summarize key pathological features of the TME and their impact on drug delivery across classical barriers, including the blood-brain, cutaneous and ocular interfaces, as well as circulating and bone-marrow niches in hematologic malignancies. We then discuss design principles of endogenous and exogenous stimuli-responsive nanoplatforms, and how these systems enable TME monitoring via liquid biopsy, spatial multi-omics and real-time imaging, and TME modulation through metabolic reprogramming, immune activation, vascular normalization and extracellular-matrix remodeling. Finally, we highlight major translational challenges and future opportunities, emphasizing the roles of artificial intelligence, multiscale and quantum-inspired modeling, and closed-loop theranostic strategies in optimizing TME-responsive nanomedicines for clinically meaningful benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, in clinical in vivo settings, these hyper-glycolytic tumors create a severely hypoxic, highly acidotic, and immunosuppressive tumor microenvironment (TME), which hinders drug penetration and promotes stemness, ultimately resulting in systemic failure and resistance (15).”
From Bioinformatics-based identification of glycolysis-related signatures associated with drug resistance and prognosis in lung adenocarcinoma (2026) · cites this paper as [15]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
Macrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332 · cited 1×
“35 As noted above, dense ECM, elevated tumor interstitial pressure and abnormal vascular perfusion within the TME jointly restrict the effective intratumoral distribution of drugs, so that simply escalating the dose rarely yields a proportional increase in therapeutic efficacy.”
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218 · cited 1×
“…highly heterogeneously in the clinic: vascular permeability and lymphatic drainage vary markedly between patients, between lesions and even among different regions within the same tumor, resulting in passive accumulation efficiencies far below those predicted from animal models 36 (Figure 2).”
Nieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., Fong, S. F. T., Csiszar, K., Giaccia, A., Weninger, W., et al. (2009) · Cell · doi:10.1016/j.cell.2009.10.027 · Cited by 4,101
Hypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645
The Tumor Microenvironment Innately Modulates Cancer Progression
Hinshaw, D. C., & Shevde, L. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3962 · Cited by 3,270
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Metastasis: from dissemination to organ-specific colonization
Nguyen, D. X., Bos, P. D., & Massagué, J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2622 · Cited by 2,649
Research works printed but not linked: 2
- Netti, 2000, Cancer Res, 60, 2497
- Gabizon, 1994, Cancer Res, 54, 987
Cited by
Parvin, N., Park, K., Jung, J. H., & Mandal, T. K. (2026) · Antibiotics · doi:10.3390/antibiotics15070638 · Cited by 4
Recent advances in hybrid membrane vesicles as a programmable biomimetic drug delivery
Chen, Y., Yuan, X., Huang, Y., Wei, Q., & Zhang, X. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115244 · Cited by 3
Rahaman, Jalouli, M., Harrath, A. H., Choi, J., Choi, M., Kim, H. S., Park, S., Shim, B., Rani, A., & Kim, B. (2026) · Cells · doi:10.3390/cells15100850 · Cited by 2
Moharana, A. K., Barik, B., & Santhosh, A. J. (2026) · Cancer Nanotechnology · doi:10.1186/s12645-026-00385-y · Cited by 1
Zhang, C., Shu, B., Wang, X., Shen, X., Du, Y., Yang, J., & Miao, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1845672 · Cited by 1
Metadata
- Authors
- He, J., Xue, W., & Li, Y.
- Affiliations
- Qinghai University (CN)
- Corresponding author
- Li, Yan
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2026-03
- Volume
- Volume 21
- Pages
- 1-38
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- PMC
- PMC13011976
- OpenAlex
- W7138845632
- Cited by
- 16
- References
- 189
- Citations by year
- 2026: 16
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Nanomedicine (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Keywords
- tumor microenvironment, stimuli-responsive nanomedicine, precision cancer therapy, drug delivery barriers, blood-brain barrier, ocular drug delivery, bone marrow microenvironment, hematologic malignancies, liquid biopsy, spatial multi-omics, real-time imaging, metabolic reprogramming, immune activation, vascular normalization, extracellular matrix remodeling, immunosuppression, treatment resistance, artificial intelligence in drug design, quantum-inspired modeling
- MeSH terms
- Theranostic Nanomedicine, Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Delivery Systems, Nanomedicine, Nanoparticles, Precision Medicine, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor Microenvironment-Responsive Nanomedicine: Monitoring and Modulating the Tumor Microenvironment for Precision Cancer Therapy. https://app.cochat.ai/papers/10.2147/ijn.s560983
- The paper
- He, J., Xue, W., & Li, Y. (2026). Tumor Microenvironment-Responsive Nanomedicine: Monitoring and Modulating the Tumor Microenvironment for Precision Cancer Therapy. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s560983
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.